RxDoctor Payments Data

Jacob Ehlert, PA

Physician Assistant · Casper, WYNPI 1073397113

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AstraZeneca at 37.3% of the total.

$974in general payments, 2019–2025

Across 35 payments — averaging $27.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$364
  • GSK$256
  • AbbVie$74
  • Edwards Lifesciences$60
  • Lundbeck LLC$41
  • Lilly USA, LLC$33
  • plus $147 from 8 others

What the payments were for

  • Food & beverage$974100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$974 in reported general payments places this provider in the 75th percentile of 203 physician assistant providers in Wyoming.

See all physician assistant providers in Wyoming

Medicare billing

Part B allowed, 2024
$50,357
Medicare patients
277
Services billed
806

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$15,519
EliquisApixaban20$12,929
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$8,190
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,349
Celecoxib23$1,874
Albuterol Sulfate HfaAlbuterol Sulfate40$834
Cyclobenzaprine Hcl27$793
Eszopiclone11$708
Duloxetine Hcl20$675
Pantoprazole Sodium32$633
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen21$565
Pregabalin12$489
Omeprazole32$429
Tamsulosin Hcl39$414
Levothyroxine Sodium50$334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$256$15,51924 claims
AstraZenecaBreztri Aerosphere$364$8,19011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 203 physician assistant providers in Wyoming.

Other physician assistant in Casper

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →